Controversial Role of Lecithin:Cholesterol Acyltransferase in the Development of Atherosclerosis: New Insights From an LCAT Activator.

While epidemiological studies have consistently shown an inverse correlation between HDL-C (high-density lipoprotein cholesterol) and cardiovascular disease, human genetic and pharmacological studies indicate that HDL-C levels may not always mirror HDL function.1,2 For this reason, recent efforts have focused on developing novel therapeutic approaches that could selectively target HDL function, in particular reverse cholesterol transport (RCT).2

[1]  Naoya Wada,et al.  Novel LCAT (Lecithin:Cholesterol Acyltransferase) Activator DS-8190a Prevents the Progression of Plaque Accumulation in Atherosclerosis Models , 2020, Arteriosclerosis, thrombosis, and vascular biology.

[2]  A. Remaley,et al.  Novel lecithin: cholesterol acyltransferase-based therapeutic approaches. , 2020, Current opinion in lipidology.

[3]  N. Kiyosawa,et al.  Activation of naturally occurring LCAT mutants by a novel activator compound , 2020 .

[4]  A. Jadhav,et al.  Molecular basis for activation of lecithin:cholesterol acyltransferase by a compound that increases HDL cholesterol , 2018, bioRxiv.

[5]  A. Remaley,et al.  Is Low-Density Lipoprotein Cholesterol the Key to Interpret the Role of Lecithin: Cholesterol Acyltransferase in Atherosclerosis? , 2018, Circulation.

[6]  G. Franceschini,et al.  Complete and Partial Lecithin: Cholesterol Acyltransferase Deficiency Is Differentially Associated With Atherosclerosis , 2018, Circulation.

[7]  Marc P. Bonaca,et al.  354Multiple ascending doses of recombinant human lecithin-cholesterol acyltransferase in patients with atherosclerosis: phase 2a primary results , 2018, European Heart Journal.

[8]  Jean-Claude Tardif,et al.  HDL and atherosclerotic cardiovascular disease: genetic insights into complex biology , 2018, Nature Reviews Cardiology.

[9]  A. Jadhav,et al.  Lecithin:Cholesterol Acyltransferase Activation by Sulfhydryl-Reactive Small Molecules: Role of Cysteine-31 , 2017, The Journal of Pharmacology and Experimental Therapeutics.

[10]  R. Shamburek,et al.  Safety and Tolerability of ACP-501, a Recombinant Human Lecithin:Cholesterol Acyltransferase, in a Phase 1 Single-Dose Escalation Study. , 2016, Circulation research.

[11]  M. Van Eck,et al.  Lecithin:cholesterol acyltransferase: old friend or foe in atherosclerosis? , 2012, Journal of Lipid Research.

[12]  N. Geoghagen,et al.  Small molecule activation of lecithin cholesterol acyltransferase modulates lipoprotein metabolism in mice and hamsters. , 2012, Metabolism: clinical and experimental.

[13]  R. Shamburek,et al.  Effect of Recombinant Human Lecithin Cholesterol Acyltransferase Infusion on Lipoprotein Metabolism in Mice , 2010, Journal of Pharmacology and Experimental Therapeutics.

[14]  M. Guerin,et al.  HDL and Reverse Cholesterol Transport , 2010 .

[15]  D. Rader,et al.  Lecithin: Cholesterol Acyltransferase Expression Has Minimal Effects on Macrophage Reverse Cholesterol Transport In Vivo , 2009, Circulation.

[16]  G. Franceschini,et al.  Functional LCAT is not required for macrophage cholesterol efflux to human serum. , 2009, Atherosclerosis.

[17]  A. Remaley,et al.  Lecithin: cholesterol acyltransferase--from biochemistry to role in cardiovascular disease. , 2009, Current opinion in endocrinology, diabetes, and obesity.

[18]  R. F. Hoyt,et al.  Cholesteryl Ester Transfer Protein Corrects Dysfunctional High Density Lipoproteins and Reduces Aortic Atherosclerosis in Lecithin Cholesterol Acyltransferase Transgenic Mice* , 1999, The Journal of Biological Chemistry.

[19]  R. F. Hoyt,et al.  High plasma HDL concentrations associated with enhanced atherosclerosis in transgenic mice overexpressing lecithinchoesteryl acyltransferase , 1997, Nature Medicine.

[20]  S. Yokoyama,et al.  Regulation of Cellular Cholesterol Efflux by Lecithin:Cholesterol Acyltransferase Reaction through Nonspecific Lipid Exchange (*) , 1996, The Journal of Biological Chemistry.

[21]  R. F. Hoyt,et al.  Overexpression of Human Lecithin Cholesterol Acyltransferase Leads to Hyperalphalipoproteinemia in Transgenic Mice (*) , 1995, The Journal of Biological Chemistry.